I think you're confused by what both Austin and I mean. Neither of us are asking about the halt. And neither of us are referring to it. We get that certain things related to strategy needs to remain quiet about until the situation resolves itself.
It is EVERYTHING else. Realistic discussions lead to realistic expectation. There is no reason to keep shareholders in the dark over all aspects. All we get from them is promotion and frustration from years of waiting for news on any of these promotional pieces to come to fruition. They have yet to come through on one promise. Even the promises that they offer a week out are faulty. Understand this, I was told Direct would be starting soon. I was a mighty upset shareholder last Spring when I read the 10K or 10Q. I forget which one is was exactly, but it was very clear to me that Direct would not move forward upon review of that document. LP's lips had just finished yapping about possibly doing THREE Direct trials simultaneously. Not one or two, the potential for THREE. Low and behold the financials reeked of manufacture build out and spending, the kind that derails clinical progress and of course I find Direct monetary delay disclosures. Why even build such false unrealistic expectations?My only wish is that I actually shared my discontent over it back then on this iHub. My bet is most wouldn't have believed we were to about to receive a long silent delay. You would never blame a customer for being upset if you told them you were going to do work, but then you never showed up to do it. Do not blame shareholders for being disgruntle when the Company reports to us that they're planning to start at least two studies within the next quarter and then go tight lipped about it on the promotional airwaves and disclose in the financial statements that there may not be enough money to do Direct studies. To me that was a lawyer move they pulled. They didn't want to retract the false expectation they themselves set. They preferred all of us to continue to believe things were on track and moving along so that we stay tuned. But yet they retracted their prior promotional words within legal statements! And of course with all things NWBT you have to read the fine print to find it. This company has more shelved projects then they do running ones. When they go off-track they opt always to say nothing. I'm still not even sure what the real delay over Direct is all about as they haven't told us. But yes, I get there are competitive pressures that can strategically alter the direction of Direct's clinical approach. What they don't get is we deserve to hear something as shareholders. This is not a private company, they are supposed to answer to us, but they don't. We deserve communication that isn't just promotional and that isn't just a pep talk. We deserve a company that is honest and forthcoming on areas they can talk about. These are not performance let downs, these are performance SHUT downs. There's a way to tell us things, and their way clearly isn't working. Their way leads to distrust. Their way hurts stock prices. But they don't care about that, as they don't have to. It benefits their pockets if the price goes low. They get more shares for their "hard" work. As does Cognate. We get frustrations, watching our shares deplete of its value. And what's the payoff of being a long term shareholder through the thick and thin of it? There is none in the short term. In the long term it's a maybe! The problem is we have no idea what term we're in as they never set realistic expectations. Folks lose the willpower to hold on. Their ability for a great stock price will only occur with clinical success, which is not a guarantee. Only those who are here in the end will see it, assuming success. But because they choose not to share information with their current shareholders, it is the latecomers who will ultimately benefit, by getting shares at depressed promotional let-down prices when current shareholders fizzle out. I can not lie, that's how I see this playing out if they don't start sharing more information soon. Cheap prices for newbies, after oldies throw in the towel. Way to go MGMT!
AI
